MediPharm Labs Australia has signed a GMP white-label supply and contract manufacturing agreement with Cannim Australia and started the registration process for the launch of over-the-counter products in Australia in 2021.
Under the initial three-year deal, MediPharm will supply a full range of specially formulated CBD and THC cannabis oil products to be sold initially under Cannim’s Lumir brand. MediPharm will also provide Cannim with contract manufacturing with their starting material.
MediPharm Labs president and interim CEO Keith Strachan said: “We are excited to partner with Cannim as the demand for high quality and novel formulations for cannabis products continues to rise along with Australia’s growing approved patient population.”
MediPharm has commenced its product registration process following the Therapeutic Goods Administration’s decision to down schedule CBD last last year.
MediPharm Labs CEO Asia Pacific Warren Everitt said: “MediPharm Labs Australia is perfectly positioned to begin manufacturing and fulfilling the demand for this new OTC segment. We have already seen interest from pharmaceutical companies looking for a GMP-certified partner to comply with the TGA minimum requirements and execute on this new growth category.”
